INmune Bio, Inc. (NASDAQ:INMB) Short Interest Up 7.0% in January

INmune Bio, Inc. (NASDAQ:INMB) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 4,280,000 shares, a growth of 7.0% from the December 31st total of 4,000,000 shares. Based on an average daily volume of 229,900 shares, the days-to-cover ratio is presently 18.6 days.

Hedge Funds Weigh In On INmune Bio

A number of large investors have recently made changes to their positions in INMB. Praetorian PR LLC lifted its stake in shares of INmune Bio by 61.0% in the 3rd quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock valued at $4,209,000 after purchasing an additional 295,800 shares during the period. Geode Capital Management LLC boosted its stake in shares of INmune Bio by 6.6% in the 3rd quarter. Geode Capital Management LLC now owns 344,466 shares of the company’s stock worth $1,857,000 after buying an additional 21,262 shares during the last quarter. State Street Corp lifted its stake in INmune Bio by 35.1% in the third quarter. State Street Corp now owns 226,428 shares of the company’s stock valued at $1,220,000 after purchasing an additional 58,838 shares during the last quarter. Marshall Wace LLP lifted its position in shares of INmune Bio by 332.1% during the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after acquiring an additional 89,091 shares in the last quarter. Finally, Westside Investment Management Inc. lifted its position in shares of INmune Bio by 26.2% during the fourth quarter. Westside Investment Management Inc. now owns 89,975 shares of the company’s stock worth $420,000 after acquiring an additional 18,660 shares in the last quarter. Institutional investors own 12.72% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. RODMAN&RENSHAW upgraded shares of INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on shares of INmune Bio in a research note on Tuesday, January 28th. They issued a “buy” rating and a $23.00 target price on the stock. Finally, Alliance Global Partners initiated coverage on INmune Bio in a report on Monday, October 21st. They set a “buy” rating and a $20.00 target price on the stock. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $20.75.

INmune Bio Stock Down 3.9 %

INMB opened at $9.76 on Tuesday. The stock has a market cap of $216.40 million, a P/E ratio of -4.48 and a beta of 1.78. INmune Bio has a 12 month low of $4.32 and a 12 month high of $14.74. The company has a fifty day simple moving average of $5.73 and a 200 day simple moving average of $6.04.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.